# Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

> **NCT03027245** · — · COMPLETED · sponsor: **Eisai GmbH** · enrollment: 353 (actual)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT03027245
- **Lead sponsor:** Eisai GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-13
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03027245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03027245, "Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03027245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*